Skip to main content
NCBI home page
Asian Pacific Journal of Cancer Prevention : APJCP logoLink to Asian Pacific Journal of Cancer Prevention : APJCP
. 2020 Jul;21(7):2131–2139. doi: 10.31557/APJCP.2020.21.7.2131

Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line

Masumeh Sanaei 1, Fraidoon Kavoosi 1,*
PMCID: PMC7573409  PMID: 32711442

Abstract

Background:

A pattern of epigenetic modifications and changes, DNA methylation and histone modification, is central to many human cancers. A variety of tumor suppressor genes (TSGs) have been demonstrated to be silenced because of histone deacetylation and DNA hypermethylation in several cancers. Recent in vitro studies have shown that two known mechanisms of epigenetic alteration consisting of methylation and histone deacetylation seem to be the best candidate mechanisms for inactivation of CIP/KIP family (p21Cip1/Waf1/Sdi1, and p27Kip1) in numerous cancers. Numerous investigations have indicated that DNA demethylating and histone deacetylase inhibitors (HDACIs) can restore the CIP/KIP family gene expression. Previously, we evaluated the effect of trichostatin A (TSA) and 5-aza-2′-deoxycytidine (5-AZA-CdR) on hepatocellular carcinoma (HCC). The present study was designed to investigate the effect of zebularine in comparison to and in combination with trichostatin A on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a and DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression, cell growth inhibition and apoptosis induction in colon cancer LS 174T cell line.

Materials and Methods:

The colon cancer LS 174T cell line was cultured and treated with zebularine and TSA. To determine cell viability, apoptosis, and the relative expression level of the genes, MTT assay, cell apoptosis assay, and qRT-PCR were done respectively.

Results:

Both compounds significantly inhibited cell growth, and induced apoptosis. Furthermore, both compounds increased p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 significantly. Additionally, zebularine and TSA decreased DNMTs and HDACs gene expression respectively.

Conclusion:

The zebularine and trichostatin A can reactivate the CIP/KIP family through inhibition of DNMTs and HDACs genes activity.

Key Words: Zebularine, trichostatin, CIP/KIP family, colon cancer

Introduction

A pattern of epigenetic modifications and changes, DNA methylation and histone modification, is central to many human cancers. Posttranslational modifications affect chromatin structure and compaction resulting in changes in cell behavior and altered gene expression. Aberrant altered epigenomic patterns and gene expression are significant features of many cancers. Epigenetic modifications comprising DNA methylation, histone methylation, and histone acetylation plays an important role in the induction and progression of numerous cancers (Ellis et al., 2009). In fact, dysregulated epigenetic modifications play a significant role in driving cancer development and progression. A variety of tumor suppressor genes (TSGs) have been demonstrated to be silenced in several cancers. Indeed, the TSGs silencing is accompanied by histone deacetylation and DNA hypermethylation (Bachman et al., 2003). The mammalian somatic cell cycle is an ordered, tightly-regulated process with multiple checkpoints. The cycle is divided into four phases comprising initial growth (G1), DNA synthesis (S), a gap (G2), and mitosis (M). The molecular machinery of the cell cycle is a family of enzymes, the cyclin-dependent kinases (Cdks). The active form of these enzymes is a complex consisting of a kinase and a cyclin. Both cyclin and Cdk are positive regulators of cell cycle progression whereas, cyclin-dependent kinase inhibitors (CKIs) are negative regulators of cell cycle which stop or break the cycle. These negative inhibitors comprise two families including INK and CIP/KIP families. The INK family consists of INK4A (p16), INK4B (p15), INK4C (p18), and INK4D (p19). The CIP/KIP family includes CIP1 (p21), KIP1 (p27), and KIP2 (p57) (Park et al., 2003). Recent in vitro studies have shown that two known mechanisms of epigenetic alteration consisting, methylation and histone deacetylation seem to be the best candidate mechanisms for inactivation of CIP/KIP family in numerous cancers such as gastric cancer (Shin et al., 2000; Borges et al., 2010), lung cancer (Fang et al., 2002), hepatocellular carcinoma (HCC), pancreatic cancers, and acute myeloid leukemia (Kikuchi et al., 2002), and colon cancer (Colo-320 and SW1116) (Fang et al., 2004). There are several reports regarding the association between overexpression of DNA methyltransferases 1, 2 and 3 and DNA methylation in various cancers comprising gastric cancer (Ding et al., 2008), colon cancer HCT116, LS180, HT29/219, Caco2, and SW742 cell lines (Sarabi et al., 2015). Furthermore, the overexpression of class I and II HDAC has been reported in colon cancer (Mariadason., 2008). Silenced TSGs are obvious targets for reactivation by DNA methyltransferase inhibitors (DNMTIs) such as 5-aza-2′-deoxycytidine (5-Aza-CdR), 5-azacytidine (5-Aza-CR) and zebularine. Numerous investigations have indicated that zebularine, a general inhibitor of DNA methylation, inhibits DNMTs in human breast cancer MDA-MB-231 and MCF-7 (Billam et al., 2010), T24 bladder carcinoma (Ben-Kasus et al., 2005), colon cancer SW480 cells, HT29, SW48 and HCT116 (Ikehata et al., 2014). Besides, it has been identified that histone deacetylase inhibitors (HDACIs) can suppress class I and II HDAC in colon cancer (Mariadason., 2008). Previously, we evaluated the effect of trichostatin A (TSA) on HCC (Sanaei et al., 2017; Sanaei et al., 2018; Leu et al., 2003) and also the effect of DNA demethylating agent 5-AZA-CdR on this cancer (Sanaei et al., 2019). The present study was designed to investigate the effect of zebularine and trichostatin A on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a and DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression, cell growth inhibition and apoptosis induction in colon cancer LS 174T cell line.

Materials and Methods

Materials

The human colon cancer LS 174T cell line was kindly provided from the National Cell Bank of Iran-Pasteur Institute and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with antibiotics and fetal bovine serum 10% in a humidified atmosphere of 5% CO2 in air at 37oC. All reagents (zebularine and TSA), kits, and instruments used in RNA extraction, reverse transcription, and real-time PCR were provided as obtained previously (Sanaei M et al., 2017; Sanaei M et al., 2018; Sanaei M et al., 2019).

Cell culture and cell viability

The colon cancer LS 174T cell viability was measured using 3 (4,5 dimethyl 2 thiazolyl) 2, 5 diphenyl 2H tetrazolium bromide (MTT) assay. The LS 174T cells were cultured and seeded in 96-well plates at a density of 4 × 105 cells per well and treated with zebularine (0, 10, 25, 50, 100, and 200 μM) and TSA (0, 1, 5, 10, 25, and 50 μM) for 24 and 48 h. The control groups were treated with Dimethyl sulfoxide (DMSO), 0.05 %, only. After incubation for 24 and 48 h, the LS 174T cells were exposed to MTT, MTT (0.5 mg/mL) was added to each well for 4 h. Finally, the MTT metabolite, the blue MTT formazan, was dissolved in DMSO (200 mL) and the optical density was detected by a microplate reader at a wavelength of 570 nM. Each experiment was repeated three times (triplicates).

Cell apoptosis assay

To determine the apoptotic LS 174T cells, the cells were treated with cultured and seeded at a density of 4 × 105 cells/well and treated with zebularine (50 μM) and TSA (5 μM) for 24 and 48 h. Following treatment, the cells were harvested by trypsin and washed twice with PBS and then resuspended in Binding buffer (1x). Subsequently, the cells were stained with annexin V-FITC (5 μl) and propidium iodide (5 μl) in the dark at room temperature for 15 min. Finally, the LS 174T apoptotic cells were counted by FACScan flow cytometry (Becton Dickinson, Heidelberg, Germany).

Real-time Quantitative Reverse Transcription PolymeraseChain Reaction (qRT-PCR)

The qRT-PCR was performed to determine the relative expression level of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a, DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) genes. The colon cancer LS 174T cells were cultured at a density of 4 × 105 cells/well and treated with zebularine (50 μM) and TSA (5 μM), as alone and combined, for 24 and 48 h, based on IC5o values. After 24 and 48 h of incubation, the total RNA was harvested using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer protocol and treated by RNasefree DNase (Qiagen). The RNA was transcribed to complementary DNA (cDNA). QRT-PCR was done to assess the expression level of the mentioned genes as described previously (Sanaei et al., 2019). The program for the PCR was as we reported previously (Sanaei et al., 2019). The primer sequences of the genes are indicated in table1. GAPDH was used as an endogenous control. Data were analyzed using the comparative Ct (ΔΔct) method.

Table 1.

The Primer Sequences of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a, DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6)

Primer Name Primer Sequences (5' to 3') References
DNMT1 Forward GAG GAA GCT GCT AAG GAC TAG TTC Sanaei et al., 2018
DNMT1 Reverse ACT CCA CAA TTT GAT CAC TAA ATC Sanaei et al., 2018
DNMT3a Forward GGA GGC TGA GAA GAA AGC CAA GGT Sanaei et al., 2018
DNMT3a Reverse TTT GCC GTC TCC GAA CCA CAT GAC Sanaei et al., 2018
P21 Forward AGG CGC CAT GTC AGA ACC GGC TGG Sanaei et al., 2019
P21 Reverse GGA AGG TAG AGC TTG GGC AGG C Sanaei et al., 2019
P 27 Forward ATG TCA AAC GTG CGA GTG TCT AAC Sanaei et al., 2019
P 27 Reverse TTA CGT TTG ACG TCT TCT GAG GCC A Sanaei et al., 2019
P 57 Forward GCGGCGATCAAGAAGCTGTC Sanaei et al., 2019
P 57 Reverse CCGGTTGCTGCTACATGAAC Sanaei et al., 2019
DNMT3b Forward TAC ACA GAC GTG TCC AAC ATG GGC Leu et al., 2003
DNMT3b Reverse GGA TGC CTT CAG GAA TCA CAC CTC Leu et al., 2003
GAPDH Forward TCCCATCACCATCTTCCA Jin et al., 2008
GAPDH Reverse CATCACGCCACAGTTTCC Jin et al., 2008
HDAC1 Forward GACACGCCAAGTGTGTGGAA Song et al., 2015
HDAC1 Reverse CCTCCCAGCATCAGCATAGG Song et al., 2015
HDAC2 Forward ACATGAGCAATGCGGAGAAAT Song et al., 2015
HDAC2 Reverse TCTGCCATCTTGTGGTACAGTGA Song et al., 2015
HDAC3 Forward CCTTTTCCAGCCGGTTATCA Song et al., 2015
HDAC3 Reverse ACAATGCACGTGGGTTGGT Song et al., 2015
HDAC4 Forward TCAGATCGCCAACACATTCG Song et al., 2015
HDAC4 Reverse ACGGGAGCGGTTCTGTTAGA Song et al., 2015
HDAC5 Forward CCATTGGAGACGTGGAGTACCT Song et al., 2015
HDAC5 Reverse GCGGAGACTAGGACCACATCA Song et al., 2015
HDAC6 Forward TCGCTGCGTGTCCTTTCAG Song et al., 2015
HDAC6 Reverse GCTGTGAACCAACATCAGCTCTT Song et al., 2015
Open in a new tab

Results

Result of cell viability by the MTT assay

To test the effect of zebularine (0, 10, 25, 50, 100, and 200 μM) and TSA (0, 1, 5, 10, 25, and 50 μM) on the colon cancer LS 174T cell viability, MTT assay was utilized. Our findings showed that the rate of cell growth inhibition was significantly increased in than that in control groups after 24 and 48 h. Results showed that the number of viable LS 174T cells decreased significantly, as the concentration of the compounds and duration increased; indicating a dose- and duration-dependent relationship (P< 0.001), Figure 1. The IC50 values were determined with approximately 50 and 5 μM for zebularine and TSA respectively.

Figure 1.

Figure 1

Open in a new tab

In Vitro Effects of Zebularine (0, 10, 25, 50, 100, and 200 μM) and TSA (0, 1, 5, 10, 25, and 50 μM) on LS 174T Cells Viability Determined by MTT Assay at 24 and 48 h. As shown, from right to the left, the first column of each group belongs to the control group. Values are means of three experiments in triplicate. Asterisks (*) demonstrate significant differences between treated and untreated control groups

Result of cell apoptosis assay

Flow cytometric analysis was achieved to determine whether zebularine (50 μM) and TSA (5 μM) can induce apoptosis in colon cancer LS 174T line. The percentage of treated and un-treated LS 174T apoptotic cells was evaluated by staining with annexin V-FITC and PI after 24 and 48 h of treatment. After treatment with zebularine and TSA, as alone and combined, the apoptosis percentage increased significantly as shown in Table 2 and Figures 2-4. Both compounds had a time-dependent manner. The apoptotic effect of TSA was stronger than that of zebularine. Further, maximum apoptosis was seen in the groups treated with combined agents, Figure 5.

Table 2.

Percentage of Apoptosis in the Groups Treated with Zebularine and TSA, as Alone and Combined, at Different Periods

Drug Dose/ μM Duration/ h Apoptosis % P-value
Zebularine 50 24 8.07 P < 0.001
50 48 10.07 P < 0.001
TSA 5 24 10.35 P < 0.001
5 48 13.8 P < 0.001
Zebularine/TSA 50/5 24 85.11 P < 0.001
50/5 48 97.43 P < 0.001
Open in a new tab

Figure 2.

Figure 2

Open in a new tab

The Apoptotic Effect of Zebularine (50 μM) on Colon Cancer LS 174T Line Cell versus Control Groups at Different Periods (24 and 48h). The cells were treated with this zebularine for 24 and 48h and then the apoptotic effect was evaluated by flow cytometric analysis. Results were obtained from three independent experiments and were expressed as mean ± standard error of the mean

Figure 4.

Figure 4

Open in a new tab

The Apoptotic Effect of Zebularine (50 μM) in Combination with TSA (5 μM) on LS 180 Cell versus Control Groups at Different Periods (24 and 48h). The cells were treated with combined agents for 24 and 48h and then the apoptotic effect was evaluated by flow cytometric analysis. Results were obtained from three independent experiments and were expressed as mean ± standard error of the mean

Figure 5.

Figure 5.

Open in a new tab

The Comparative Apoptotic Effects of Zebularine (50 μM) in Comparison to and in Combination with TSA (5 μM) on LS 174T Cells. Asterisks (*) indicate significant differences between the treated and untreated control groups. As demonstrated above, TSA had a more significant apoptotic effect on LS 174T cells in comparison to zebularine. The combined treatment had a maximum effect on apoptosis

Result of determination of genes expression

The effect of zebularine (50 μM) and TSA (5 μM) on the p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a, DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression was investigated by quantitative real-time RT-PCR analysis. The result indicated that treatment of LS 174T cells with zebularine (50 μM) and TSA (5 μM) for 24 and 48 h reactivated the p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2 gene, down-regulated DNMT1, DNMT3a, DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression. The CIP/KIP family (p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2) genes were more sensitive to TSA compared with zebularine. It means that TSA had a more significant effect on the up-regulation of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, Figures 6-9.

Figure 6.

Figure 6

Open in a new tab

The Relative Expression Level of DNA Methyltransferases (DNMT1, 3a, and 3b), p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 in the LS 174T Cell Line Treated with Zebularine (50 μM) versus Untreated Control Groups at Different Periods (24 and 48h). The first column of each group belongs to the untreated control group and the others belong to the treated cells with zebularine. Asterisks (*) indicate significant differences between the treated and untreated groups

Figure 9.

Figure 9

Open in a new tab

The Relative Expression Level of p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 in the LS 174T Cell Line Treated with Zebularine (50 μM) and TSA (5 μM), Individually and Combined, versus Untreated Control Groups at Different Periods (24 and 48h). The first column of each group belongs to the untreated control group and the others belong to the treated cells with the zebularine and TSA. Asterisks (*) indicate significant differences between the treated and untreated groups

Discussion

The mammalian cell cycle is regulated via interactions between cyclins and a family of negative cell cycle regulators classified into two families, the CIP/KIP family, and the INK4 family. DNA methylation patterns and histone deacetylation of these families strongly correlate with tumorigenesis (Tsou et al., 2002). DNA methylation is catalyzed by DNMT1, DNMT3a, and DNMT3b. Furthermore, histone deacetylation is catalyzed by HDACs. Therefore, DNMTs and HDACs induce hypermethylation and histone deacetylation respectively resulting in TSGs transcriptional repression and cancer induction (Li et al., 2007). The DNMTIs and HDACIs can reactivate epigenetically silenced TSGs (Yan et al., 2015). In the present study, zebularine and TSA reactivated the p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2 gene, down-regulated DNMT1, DNMT3a, DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene resulting in cell growth inhibition and apoptosis induction. The CIP/KIP family (p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2) gene was more sensitive to TSA compared with zebularine. It means that TSA had a more significant effect on the up-regulation of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2. In consistent with our result, it has been reported that zebularine can restore p21Cip1/Waf1/Sdi1 in colon cancer SW48 and HT-29 (Flis et al., 2014), CT15 and HT-29 colon cancer (Cheng et al., 2004). The other members of the DNMTI family act by the same pathway as reported for 5-azacitidine. It reactivates p21Cip1/Waf1/Sdi1in HCT 116 colon cancer cells (Jiemjit et al., 2008), p27Kip1 in colon cancer SW1116 cells (Lu et al., 2007), Caco2, RKO, SW48, SW480, Colo201, Colo205, Colo320, BM314, DLD-1, and HT29 (Kikuchi et al 2002). Further, we evaluated the molecular mechanism through which zebularine reactivate p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2 gene and found that this agent targets some of DNMTIs (DNMT1, DNMT3a, and DNMT3b). A similar mechanism (DNMT inhibition) has been demonstrated in colon cancer HCT116 cells (Yang et al., 2013), HCC Hep G2 (Nakamura et al., 2013), cholangiocarcinoma cell lines TFK-1 and HuCCT1 (Nakamura et al., 2015). After assessment of the effect of TSA on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2 gene expression, we further determined the effect of TSA on Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression. As we reported, this agent down-regulated both Class I and II HDACs. Similarly, it has been shown that TSA down-regulates class I and II HDACs in colon cancer cells SW620, SW480, and DLD1 (Krishnan et al., 2010), class I and II HDACs in human prostate cancer LNCaP cells (Thakur et al., 2011). Further molecular mechanisms of TSA including down-regulation of HDAC8 in colon cancer cell line SW620 (Hu et al., 2003), HDACs 5 and 8 in lung cancer, breast cancer, and skin cancer cells (Chang et al., 2012). As mentioned above, we only evaluated the effect of TSA on Class I and II HDACs in colon cancer. Therefore, the investigation of TSA on the other classes of HDACs is recommended.

In summary, our findings indicated that zebularine and TSA can down-regulate DNMT1, DNMT3a, DNMT3b, class I HDACs (HDACs 1, 2, 3) and class II HDACs (HDACs 4, 5, 6) resulting in reactivation of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, cell growth inhibition and apoptosis induction of colon cancer LS 174T cell line.

Table 3.

The Relative Expression Level of DNMTs (DNMT1, DNMT3a, and DNMT3b), CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2) HDAC1, HDAC2, and HDAC3 Genes

Cell line Gene Drug Dose (μM) Duration (h) Expression P-value
LS 174T DNMT1 Zebularine 50 24 0.7 0.023
LS 174T DNMT1 Zebularine 50 48 0.55 0.001
LS 174T DNMT3a Zebularine 50 24 0.68 0.014
LS 174T DNMT3a Zebularine 50 48 0.5 0.001
LS 174T DNMT3b Zebularine 50 24 0.67 0.011
LS 174T DNMT3b Zebularine 50 48 0.44 0.01
LS 174T P21 Zebularine 50 24 1.7 0.004
LS 174T P21 Zebularine 50 48 1.9 0.001
LS 174T P27 Zebularine 50 24 1.8 0.001
LS 174T P27 Zebularine 50 48 2.1 0.001
LS 174T P57 Zebularine 50 24 1.6 0.001
LS 174T P57 Zebularine 50 48 2 0.001
LS 174T HDAC1 Trichostatin A 5 μM 24 0.58 0.001
LS 174T HDAC1 Trichostatin A 5 μM 48 0.4 0.001
LS 174T HDAC2 Trichostatin A 5 μM 24 0.56 0.002
LS 174T HDAC2 Trichostatin A 5 μM 48 0.38 0.001
LS 174T HDAC3 Trichostatin A 5 μM 24 0.57 0.001
LS 174T HDAC3 Trichostatin A 5 μM 48 0.37 0.001
LS 174T P21 Trichostatin A 5 μM 24 2.2 0.001
LS 174T P21 Trichostatin A 5 μM 48 2.8 0.001
LS 174T P27 Trichostatin A 5 μM 24 2 0.001
LS 174T P27 Trichostatin A 5 μM 48 2.4 0.001
LS 174T P57 Trichostatin A 5 μM 24 2.3 0.001
LS 174T P57 Trichostatin A 5 μM 48 2.7 0.001
Open in a new tab

Figure 3.

Figure 3

Open in a new tab

The Apoptotic Effect of TSA (5 μM) on Colon Cancer LS 174T Line Cell versus Control Groups at Different Periods (24 and 48h). The cells were treated with this zebularine for 24 and 48h and then the apoptotic effect was evaluated by flow cytometric analysis. Results were obtained from three independent experiments and were expressed as mean ± standard error of the mean

Table 4.

The Relative Expression Level of p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2 Genes in the Groups Treated with Combined Treatment

Cell line Gene Drug Dose (μM) Duration (h) Expression P-value
LS 180 P21 Zebularine/TSA 25/5 μM 24 3.2 0.001
LS 180 P21 Zebularine/TSA 25/5 μM 48 3.5 0.001
LS 180 P27 Zebularine/TSA 25/5 μM 24 3.6 0.001
LS 180 P27 Zebularine/TSA 25/5 μM 48 3.9 0.001
LS 180 P57 Zebularine/TSA 25/5 μM 24 3.7 0.001
LS 180 P57 Zebularine/TSA 25/5 μM 48 3.8 0.001
Open in a new tab

Figure 7.

Figure 7.

Open in a new tab

The Relative Expression Level of Class I HDACs (HDACs 1, 2, 3), Class II HDACs (HDACs 4, 5, 6), p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 Gene in the LS 174T Cell Line Treated with TSA (5 μM) versus Untreated Control Groups at Different Periods (24 and 48h). The first column of each group belongs to the untreated control group and the others belong to the treated cells with TSA. Asterisks (*) indicate significant differences between the treated and untreated groups

Figure 8.

Figure 8

Open in a new tab

The Relative Expression Level of p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 in the LS 174T Cell Line Treated with Zebularine (50 μM) in Combination with TSA (5 μM) versus Untreated Control Groups at Different Periods (24 and 48h). The first column of each group belongs to the untreated control group and the others belong to the treated cells with the combined components. Asterisks (*) indicate significant differences between the treated and untreated groups

Acknowledgments

This article was supported by the adjutancy of research of Jahrom University of Medical Sciences, Iran.

Conflict of interest

The authors report no conflict of interest.

References

  1. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell. 2003;3:89–95. doi: 10.1016/s1535-6108(02)00234-9. [DOI] [PubMed] [Google Scholar]
  2. Ben-Kasus T, Ben-Zvi Z, Marquez VE, et al. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol. 2005;70:121–33. doi: 10.1016/j.bcp.2005.04.010. [DOI] [PubMed] [Google Scholar]
  3. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010;120:581–92. doi: 10.1007/s10549-009-0420-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borges BDN, BURBANO RMR, et al. Absence of CIP1/KIP1 hypermethylation in gastric cancer patients from Northern Brazil. In Vivo. 2010;24:579–82. [PubMed] [Google Scholar]
  5. Chang J, Varghese D, Gillam M, et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer. 2012;106:116. doi: 10.1038/bjc.2011.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004;6:151–8. doi: 10.1016/j.ccr.2004.06.023. [DOI] [PubMed] [Google Scholar]
  7. Ding W-J, Fang J-Y, Chen X-Y, et al. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci. 2008;53:2083–9. doi: 10.1007/s10620-007-0145-2. [DOI] [PubMed] [Google Scholar]
  8. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8:1409–20. doi: 10.1158/1535-7163.MCT-08-0860. [DOI] [PubMed] [Google Scholar]
  9. Fang JY, Chen YX, Juan L, et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. Cell Res. 2004;14:217. doi: 10.1038/sj.cr.7290222. [DOI] [PubMed] [Google Scholar]
  10. Fang J-Y, Lu Y-Y. Effects of histone acetylation and DNA methylation on p21WAF1 regulation. World J Gastroenterol. 2002;8:400. doi: 10.3748/wjg.v8.i3.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Flis S, Gnyszka A, Flis K. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One. 2014;9:92305. doi: 10.1371/journal.pone.0092305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hu E, Dul E, Sung C-M, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther. 2003;307:720–8. doi: 10.1124/jpet.103.055541. [DOI] [PubMed] [Google Scholar]
  13. Ikehata M, Ogawa M, Yamada Y, et al. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol Pharm Bull. 2014;37:67–73. doi: 10.1248/bpb.b13-00574. [DOI] [PubMed] [Google Scholar]
  14. Jiemjit A, Fandy T, Carraway H, et al. p21 WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage. Oncogene. 2008;27:3615. doi: 10.1038/sj.onc.1211018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jin KL, Pak JH, Park J-Y, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol. 2008;19:185–90. doi: 10.3802/jgo.2008.19.3.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kikuchi T, Toyota M, Itoh F, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 2002;21:2741. doi: 10.1038/sj.onc.1205376. [DOI] [PubMed] [Google Scholar]
  17. Krishnan M, Singh AB, Smith J, et al. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene. 2010;29:305. doi: 10.1038/onc.2009.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Leu Y-W, Rahmatpanah F, Shi H, et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 2003;63:6110–5. [PubMed] [Google Scholar]
  19. Li L-C, Dahiya R. Epigenetics of prostate cancer. Front Biosci. 2007;12:3377–97. doi: 10.2741/2320. [DOI] [PubMed] [Google Scholar]
  20. Lu R, Wang X, Chen Z-F, et al. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem. 2007;282:12249–59. doi: 10.1074/jbc.M608525200. [DOI] [PubMed] [Google Scholar]
  21. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008;3:28–37. doi: 10.4161/epi.3.1.5736. [DOI] [PubMed] [Google Scholar]
  22. Nakamura K, Aizawa K, Nakabayashi K, et al. DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis. PLoS One. 2013;8:54036. doi: 10.1371/journal.pone.0054036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nakamura K, Nakabayashi K, Aung KH, et al. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One. 2015;10:0120545. doi: 10.1371/journal.pone.0120545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Park M-T, Lee S-J. Cell cycle and cancer. J Biochem Mol Biol. 2003;36:60–5. doi: 10.5483/bmbrep.2003.36.1.060. [DOI] [PubMed] [Google Scholar]
  25. Sanaei M, Kavoosi F. Effects of 5-aza-2’-deoxycytidine and Valproic Acid on Epigenetic-modifying DNMT1 Gene Expression, Apoptosis Induction and Cell Viability in Hepatocellular Carcinoma WCH-17 cell line. Iran J Pediat Hematol Oncol. 2019;9:17–23. [Google Scholar]
  26. Sanaei M, Kavoosi F. Effect of 5-aza-2’-deoxycytidine in comparison to valproic acid and trichostatin A on histone deacetylase 1, DNA methyltransferase 1, and CIP/KIP family (p21, p27, and p57) genes expression, cell growth inhibition, and apoptosis induction in colon cancer SW480 cell line. Adv Biomed Res. 2019;8:52. doi: 10.4103/abr.abr_91_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sanaei M, Kavoosi F. Effect of curcumin and trichostatin A on the expression of DNA methyltransfrase 1 in hepatocellular carcinoma cell line hepa 1-6. Iran J Pediat Hematol Oncol. 2018;8:193–201. [Google Scholar]
  28. Sanaei M, Kavoosi F, Roustazadeh A, et al. Effect of genistein in comparison with trichostatin a on reactivation of DNMTs genes in hepatocellular carcinoma. J Clin Translat Hepatol. 2018;6:141. doi: 10.14218/JCTH.2018.00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sanaei M, Kavoosi F, Salehi H. Genistein and trichostatin a induction of estrogen receptor alpha gene expression, apoptosis and cell growth inhibition in hepatocellular carcinoma HepG 2 cells. Asian Pac J Cancer Prev. 2017;18:3445. doi: 10.22034/APJCP.2017.18.12.3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sarabi MM, Naghibalhossaini F. Association of DNA methyltransferases expression with global and gene-specific DNA methylation in colorectal cancer cells. Cell Biochem Funct. 2015;33:427–33. doi: 10.1002/cbf.3126. [DOI] [PubMed] [Google Scholar]
  31. Shin J-Y, Kim H-S, Park J, et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res. 2000;60:262–5. [PubMed] [Google Scholar]
  32. Song J, Jin E-H, Kim D, et al. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA Clinical. 2015;3:79–89. doi: 10.1016/j.bbacli.2014.11.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis. 2011;33:377–84. doi: 10.1093/carcin/bgr277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002;21:5450–61. doi: 10.1038/sj.onc.1205605. [DOI] [PubMed] [Google Scholar]
  35. Yan B, Li X, Johnson A, et al. Epigenetic drugs for cancer therapy. Epigenet Gene Exp Regulat. 2015;18:397–423. [Google Scholar]
  36. Yang P-M, Lin Y-T, Shun C-T, et al. Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress. Sci Rep. 2013;3:3219. doi: 10.1038/srep03219. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Asian Pacific Journal of Cancer Prevention : APJCP are provided here courtesy of West Asia Organization for Cancer Prevention

RESOURCES